---
title: "Immortality Index: A Binary Milestone Registry for Longevity Research"
subtitle: "A Decentralized Peer-to-Peer Error-Correction Architecture for the Mitigation of Somatic Identity Loss and Epigenetic Drift"
authors: "Immortality Index"
affiliation: "Independent Distributed Research Infrastructure"
date: "2026"
doi: "10.5281/zenodo.PLACEHOLDER"
keywords:
  - Engineered Negligible Senescence (ENS)
  - Somatic Identity Verification
  - Fault-Tolerant Biological Networks
  - Paracrine-Mediated Remodeling
  - Bio-orthogonal Surveillance
---

# Immortality Index: A Binary Milestone Registry for Longevity Research

**Subtitle:** A Decentralized Peer-to-Peer Error-Correction Architecture for the Mitigation of Somatic Identity Loss and Epigenetic Drift
**Authors:** Immortality Index
**Institutional Affiliation:** Independent Distributed Research Infrastructure
**Publication Type:** Open-Access Preprint
**Preprint DOI:** 10.5281/zenodo.PLACEHOLDER
**Keywords:** Engineered Negligible Senescence (ENS), Somatic Identity Verification, Fault-Tolerant Biological Networks, Paracrine-Mediated Remodeling, Bio-orthogonal Surveillance

---

## Abstract

Biological aging constitutes a progressive, multi-system accumulation of entropic failure across two interacting substrates: epigenetic configuration — herein termed cellular software — and somatic mutational burden, comprising the hardware layer. Current translational longevity research is impeded by the absence of standardised, falsifiable progress metrics, with prevailing tracking methodologies relying on heterogeneous biomarker panels and non-reproducible clinical endpoints that resist formal integration. Meta-analytic power is systematically degraded by this fragmentation, and the resulting literature permits indefinite equivocation on whether any current intervention demonstrably extends maximum, rather than average, lifespan. The present paper introduces the Radical Longevity Index (RLI), a quantitative, dependency-graph-based framework that formalises 24 system-level integration bottlenecks — culminating in a single System-Level Integration Bottleneck (SLIB) validation target — across two independent research tracks: Track 01 (Somatic Genetic Maintenance) and Track 02 (Autonomous Nanorobotic Intervention). Each graph node corresponds to a discrete, falsifiable milestone cluster with binary completion semantics, enforced by a predetermined validation hierarchy progressing from in vitro human organoid models through in vivo murine assays, non-human primate longitudinal studies, and controlled human clinical trials. This paper provides a detailed mechanistic exposition of two critical Phase 4 architectural nodes: G-4.2, the paracrine-mediated intercellular epigenetic remodelling engine implementing vesicle-mediated transcriptomic cross-verification across adjacent cell populations, and G-4.4, the somatic identity triage protocol implementing a two-of-three spatial quorum logic gate that transitions terminally corrupted cells into inert, non-secretory fibrotic encapsulation. The intersection of G-4.4 with Track 02 nanorobotic units closes the error-correction loop through a bio-orthogonal tracking peptide secreted at a threshold of ≥10 fmol/mL, enabling programmatic genomic repair and eliminating Byzantine fault propagation. The paper further documents the automated AI literature scanning pipeline that sustains daily RLI state updates with deterministic, bias-free milestone evaluation enforcing strict inclusion criteria including minimum sample thresholds, statistical significance requirements, and independent replication constraints.

---

## 1. Introduction and Systems-Theoretical Framework

### 1.1 The Measurement Crisis in Translational Longevity Research

The central impediment to progress in translational biogerontology is not the absence of plausible biological interventions but the absence of a coherent, falsifiable measurement infrastructure through which to evaluate them. Contemporary longevity research is characterised by methodological fragmentation: independent laboratories report results using heterogeneous epigenetic clock implementations (Horvath first-generation methylation arrays vs. GrimAge proteomics-adjusted models vs. DunedinPACE longitudinal rate estimators), unstandardised physical performance endpoints of varying sensitivity, serum proteomics panels of variable composition and platform, and self-reported subjective wellbeing measures that lack any plausible mechanistic connection to maximum lifespan extension.

The structural consequence of this fragmentation is that no cross-study synthesis can reliably distinguish genuine biological age reduction from assay-specific artefacts, population selection bias, or regression to the mean in high-variance biomarker panels. Translational claims built on this literature are therefore systematically underdetermined relative to their stated ambitions. The longevity research field lacks a formal dependency graph: a representation of the ordered, prerequisite relationships among the discrete mechanistic capabilities that must be demonstrated, in sequence, before indefinite somatic maintenance can be achieved. Without such a graph, the field cannot distinguish incremental progress from locally optimal stagnation points, cannot identify the rate-limiting bottleneck at any given moment, and cannot coordinate distributed research investment toward a shared completion criterion. Every major engineering discipline — from semiconductor fabrication to aerospace systems integration — maintains such a graph. The Radical Longevity Index (RLI) is the first formal attempt to construct it for the longevity domain.

### 1.2 Defining Somatic Identity as a Formal Invariant

The concept of somatic identity — the persistent, verifiable correspondence between a cell's current functional state and its original encoded transcriptomic configuration — can be formalised as follows. Let a cell *c* at time *t* possess a transcriptomic state vector **T**(*c*, *t*) ∈ ℝⁿ, where *n* indexes the full expressed gene set. Let the reference configuration for that cell lineage be **T**₀(*c*), established at differentiation and stored in a lineage-matched reference atlas derived from single-cell transcriptomic profiling of embryonic and early postnatal tissue. Somatic identity integrity *I*(*c*, *t*) is defined as:

> *I*(*c*, *t*) = 1 − *d*(**T**(*c*, *t*), **T**₀(*c*)) / *d*_max

where *d* is the Jensen-Shannon divergence computed over normalised log-CPM expression profiles and *d*_max is the maximum tolerable drift threshold calibrated against the empirical distribution of drift scores in age-matched non-pathological donors. A cell is classified as identity-intact if and only if *I*(*c*, *t*) ≥ *θ*_I, and identity-corrupted otherwise.

This definition is operationalised in the RLI framework through a dual-substrate measurement system. The first substrate is the transcriptomic drift score computed as above. The second substrate is a synthetic genomic identity tag: a 48-base-pair bio-orthogonal sequence inserted into a predetermined transcriptionally inert non-coding locus — confirmed as non-functional by comprehensive ENCODE regulatory element annotation — during the initial cellular engineering phase. The tag encodes a cell-lineage-specific checksum verified periodically via locked nucleic acid (LNA) probe hybridisation with single-nucleotide mismatch discrimination. A cell must maintain both transcriptomic concordance above *θ*_I and identity tag checksum validity to be classified as identity-intact. The logical conjunction of these two independent measurements constitutes the two-channel verification architecture underlying the G-4.4 triage protocol and is designed to resist false-positive corruption calls arising from transient physiological transcriptomic perturbations that do not affect genomic sequence integrity.

### 1.3 The Validation Hierarchy as an Epistemological Constraint

A central axiom of the RLI framework is the strict, non-negotiable progression of experimental validation through four ordered tiers. Milestone completion cannot be asserted on the basis of evidence from any single experimental tier in isolation; completion at each stage is a necessary but insufficient condition for advancement. This axiom is grounded in the documented history of translational failure in biomedical research, where interventions demonstrating robust efficacy in cell culture and rodent models have failed in primate and human contexts at rates exceeding 95% for complex multi-target interventions. The four validation tiers are:

**Tier 1 — In Vitro Human Organoid Models.** Three-dimensional organotypic cultures derived from iPSCs or primary human cells, recapitulating tissue-specific architecture and paracrine microenvironments with sufficient fidelity to permit mechanistic proof-of-concept in a controlled, genetically defined human cellular context. Primary confounds include the absence of systemic vascular supply, immune cell infiltration, and endocrine regulation.

**Tier 2 — In Vivo Murine Models.** Standard inbred laboratory strains (C57BL/6J or appropriate congenic background) providing whole-organism physiological integration and longitudinal ageing readouts. Constrained by the approximately 30-fold compression of murine versus human lifespan, constitutive telomerase activity in mouse somatic cells absent in most human somatic lineages, and a lower oncogenic threshold relative to human tissue.

**Tier 3 — Non-Human Primate Longitudinal Studies.** Preferentially *Macaca mulatta* (rhesus macaque) given the validated concordance of rhesus and human Horvath methylation clock dynamics and 93% protein sequence identity with human orthologues across the Track 01 target set. NHP studies represent the minimum systemic fidelity threshold below which extrapolation to human clinical safety parameters is not epistemically justified.

**Tier 4 — Controlled Human Clinical Trials.** Phase I/II trials filed under an Investigational New Drug (IND) application with pre-specified safety endpoints comprising full oncology screening, karyotype assessment by whole-genome sequencing at annual intervals, and autoimmune panel (ANA, anti-dsDNA, complement C3/C4). Phase II/III efficacy trials must specify a minimum five-year primary observation window with biological age confirmed by two independent epigenetic clock platforms with non-overlapping feature sets.

---

## 2. The Radical Longevity Index: Dependency Graph Architecture

### 2.1 Graph Structure and Completion Semantics

The RLI is a directed acyclic graph (DAG) *G* = (*V*, *E*) in which each vertex *v* ∈ *V* represents a discrete research obstacle characterised by a precisely specified theoretical target and a set of four milestones *m*₁ through *m*₄ corresponding to the four validation tiers. An edge (*u*, *v*) ∈ *E* denotes that obstacle *u* must reach full four-milestone completion before research investment in obstacle *v* yields interpretable results at the Tier 3 or 4 level — i.e., *u* is a strict prerequisite of *v* in the translational dependency chain.

Obstacle completion is binary: an obstacle *v* is complete if and only if all four of its milestones *m*₁–*m*₄ are independently confirmed complete by evidence satisfying the inclusion criteria detailed in Section 4. Partial completion states are tracked at the milestone level and displayed as incremental progress in the public-facing RLI dashboard, but confer no graph-level completion status to the parent obstacle and do not unlock dependent obstacles. This binary gate structure prevents the premature redirection of research effort toward dependent obstacles on the basis of incomplete upstream evidence — a failure mode responsible for numerous costly translational dead ends in prior cell therapy programmes.

The current RLI instantiation comprises 25 obstacles distributed across two research tracks and five sequential phases. Twenty-four constitute the ordered dependency bottlenecks; the twenty-fifth on each track is the System-Level Integration Bottleneck (SLIB): the single convergence node at which all upstream capabilities must operate simultaneously in a living human subject.

### 2.2 Track 01: Somatic Genetic Maintenance (G-Series, 15 Obstacles)

Track 01 encompasses 15 obstacles across five phases targeting the full restoration and indefinite maintenance of genomic and epigenetic integrity in human somatic cells.

**Phase 1** establishes baseline cellular substrate integrity. G-1.1 addresses telomere length homeostasis: enzymatic telomere extension via TERT/TERC complex reconstitution in primary human somatic cells without inducing oncogenic transformation, validated by maintained replicative capacity across ≥60 additional population doublings in iPSC-derived tissue organoids with clean whole-genome sequencing at each 15-doubling checkpoint, followed by NHP demonstration of sustained telomere length maintenance in ≥80% of sampled haematopoietic and epithelial cells at 12-month follow-up.

**Phase 2** targets the epigenetic layer. G-2.1 addresses reversal of age-associated CpG methylation drift, requiring Horvath clock biological age reduction ≥20% in murine models via dCas9-DNMT3A/TET1 targeted epigenetic editing maintained over a 12-month longitudinal window. G-2.2 addresses histone modification landscape restoration, requiring reconstruction of youthful H3K27me3 and H3K4me3 bivalent domain distributions at lineage-specific developmental gene loci confirmed by CUT&RUN profiling in human organoids and ChIP-seq in murine models.

**Phase 3** advances to targeted genetic repair across four obstacles (G-3.1 through G-3.4) addressing base-excision repair pathway enhancement, CRISPR-based correction of accumulated oncogenic single-nucleotide variants, mitochondrial DNA heteroplasmy reduction, and retroelement silencing via KRAB-dCas9 targeting of HERVK and LINE-1 element families. The technical challenge of Phase 3 lies not in the availability of individual editing tools but in the combinatorial tissue delivery specificity required: simultaneous targeting of multiple loci across the full somatic tissue repertoire without off-target mutational burden exceeding one unintended edit per 10⁸ base pairs per cell generation.

**Phase 4** constitutes the intercellular communication layer and the architectural focus of this paper. Five obstacles (G-4.1 through G-4.5) address the systemic integration of single-cell correction mechanisms into a coordinated, organ-level homeostatic network. G-4.1 establishes cell-autonomous quality control via synthetic autophagy enhancement circuits. G-4.2 and G-4.4 are examined in mechanistic detail in Section 3. G-4.3 addresses vascular endothelial identity verification and repair. G-4.5 — Full Chromosomal Integration and Identity Verification — is the final Phase 4 prerequisite: concurrent deployment of all 13 Track 01 genetic subsystems in a single NHP subject, with identity tag readability confirmed in ≥85% of sampled cells across ≥5 tissue types, karyotype stability confirmed by whole-genome sequencing at 6 and 12 months, and no oncogenic events detected.

**Phase 5** contains the single Track 01 SLIB: G-5.1, Perpetual Human Somatic Rejuvenation. The theoretical target is indefinite maintenance of biological age homeostasis at a Horvath clock equivalent of ≤30 years in a living human subject receiving the full integrated Track 01 protocol — all 13 genetic subsystems active simultaneously — over a minimum five-year primary observation window, confirmed by peer-reviewed publication with zero cumulative oncogenic events, no immune dysregulation, and identity tag readability in ≥85% of sampled cells at each annual assessment.

### 2.3 Track 02: Autonomous Nanorobotic Intervention (N-Series, 10 Obstacles)

Track 02 encompasses 10 obstacles across four phases targeting the development, miniaturisation, bio-interfacing, and clinical deployment of autonomous nano-scale agents capable of real-time somatic surveillance and physically targeted genomic repair. Track 02 operates in parallel with Track 01 throughout its Phase 1–3 development arc and converges with Track 01 at the Phase 4 integration layer, where the two tracks form a mutually reinforcing closed-loop error-correction system. The Track 02 SLIB, N-4.1, requires the integrated deployment of ≥10⁶ nanorobotic units per cubic centimetre of target tissue with full autonomy, BTP-G44 detection capability, sub-10 nm repair precision, and confirmed biocompatibility across a five-year NHP longitudinal study with clean annual safety panels.

---

## 3. Core Architecture: Decentralised Cellular Fault Tolerance

### 3.1 The Error Propagation Problem in Somatic Networks

A fundamental challenge confronting any somatic maintenance architecture is the network-theoretic problem of non-silent fault propagation. A cell experiencing identity corruption — through epigenetic drift, somatic mutation accumulation, retroelement activation, or mitochondrial heteroplasmy shift — does not fail silently. It actively secretes paracrine signals and participates in intercellular communication networks that can propagate corrupted functional states to neighbouring cells. This is the biological analogue of the Byzantine fault problem in distributed computing: a node that fails non-silently, transmitting incorrect state information that other nodes process in the absence of a reliable ground truth reference.

Uncorrected, Byzantine somatic faults exhibit positive feedback dynamics. At the sub-cellular level, corrupted epigenetic configurations are transferred via exosomal miRNA cargo to adjacent cells, shifting their chromatin accessibility in a drift-amplifying direction. At the population level, cells that acquire senescence-associated secretory phenotype (SASP) profiles release pro-inflammatory cytokines — including IL-6, IL-8, TNF-α, and MMP-3 — that induce secondary epigenetic drift in proximal tissue. At the tissue level, accumulating oncogenic mutations can confer proliferative advantages that cause corrupted cell lineages to outcompete intact lineages over time, producing the clonal expansion dynamics observed in clonal haematopoiesis of indeterminate potential (CHIP) and age-associated monoclonal B-cell lymphocytosis.

The architectural response in the RLI framework is a three-layer, decentralised error-correction system: the intercellular paracrine remodelling layer (G-4.2), the individual cell triage and quarantine layer (G-4.4), and the nanorobotic physical repair and reintegration layer (N-4.1). These three layers address error propagation at the signal, cell, and genome levels respectively, providing redundancy across failure modes that any single-layer architecture would be unable to suppress.

### 3.2 G-4.2: Paracrine-Mediated Epigenetic and Transcriptomic Remodelling

The G-4.2 architecture implements a population-level continuous error-correction engine in which cells monitor their own transcriptomic drift relative to a lineage reference atlas and cross-verify their state against that of their spatial neighbours, executing localised epigenetic corrections via vesicle-mediated RNA transfer.

**Classification and gradient dynamics.** Each cell in the engineered tissue network maintains a continuously updated integrity score *I*(*c*, *t*). Cells with *I*(*c*, *t*) ≥ *θ*_low = 0.95 are classified as reference-class cells and participate as active correction donors. Cells in the range [0.80, 0.95) are classified as drift-susceptible and become preferential recipients of corrective vesicular cargo. Cells below 0.80 are forwarded to the G-4.4 triage pipeline. This three-tier classification creates a spatially organised, gradient-driven correction field across the tissue architecture, concentrating corrective vesicular flux toward cells of highest immediate need.

**Exosome cargo engineering.** The physical carrier for intercellular epigenetic correction is the exosome — a 30–150 nm extracellular vesicle derived from the late endosomal compartment via multivesicular body fusion with the plasma membrane. Reference-class cells are engineered via stable lentiviral integration to constitutively produce an enriched exosome population loaded by a synthetic RNA-sorting circuit packaging three functionally distinct cargo categories:

*Category I — Silencing agents.* siRNAs and guide RNAs targeting mRNAs of transcription factors aberrantly upregulated during epigenetic drift, prioritised by ranked frequency in single-cell transcriptomic drift surveys of aged human tissue. Primary targets include HMGA2, EZH1/EZH2 stoichiometry disruptors, and KDM6A/KDM6B.

*Category II — Chromatin remodelling effectors.* miRNAs with validated roles in re-establishing youthful chromatin accessibility landscapes: the let-7 superfamily (HMGA2 and IMP1 suppression), the miR-29 cluster (DNMT3A/3B expression reset), and miR-34a (p53 pathway modulation relevant to senescence reversal).

*Category III — Template and protein cargo.* mRNA species encoding epigenetic maintenance proteins attenuated during drift, delivered in translation-competent lipid nanoparticle-associated form. Priority targets include DNMT3A full-length isoform, SIRT1, Polycomb Repressive Complex 2 components (EED, SUZ12), and PARP1 for base-excision repair pathway reinforcement.

**Safety constraints on donor cell eligibility.** A critical safety constraint prevents erroneously corrupted reference-class cells from packaging and transmitting partially drifted cargo. A synthetic gene circuit holds the exosome biogenesis pathway (RAB27A-driven MVB docking) inactive via a constitutively expressed repressor protein titrated against real-time integrity score output. Only cells maintaining *I*(*c*, *t*) ≥ 0.92 for a sustained ≥6-hour window contribute to the active correction exosome pool. Transient drops below threshold during circadian oscillations or stress responses pause production until the sustained threshold is re-established.

The G-4.2 theoretical target requires ≥40% reduction in population-level transcriptomic drift variance across a human iPSC-derived organoid network within 72 hours, with maintained correction over 30 days and confirmed absence of anomalous silencing at identity-tag loci. NHP validation requires sustained inter-tissue epigenetic variance reduction ≥30% relative to age-matched unengineered controls over 12 months with maintained safety panels.

### 3.3 G-4.4: The Somatic Identity Triage Protocol

The G-4.4 protocol addresses the terminal failure mode beyond the remediation capacity of G-4.2: cells that have crossed the corruption threshold and whose state is too severely compromised for vesicle-mediated correction to restore identity integrity within a clinically acceptable timeframe. For such cells, the appropriate architectural response is quarantine: the controlled, irreversible transition to a permanently inert, non-proliferative, non-secretory state that eliminates Byzantine fault contribution to the network while preserving physical space for orderly nanorobotic repair or apoptotic clearance.

**The two-of-three spatial quorum logic gate.** Quarantine initiation requires satisfaction of at least two of the following three independent conditions:

*Condition A — Sustained transcriptomic corruption:* *I*(*c*, *t*) < 0.80, sustained continuously for ≥48 hours without recovery, confirmed by a real-time cell-autonomous fluorescent reporter circuit linked to the drift score output.

*Condition B — Identity tag checksum failure:* The synthetic genomic identity tag fails independent LNA probe sequence verification in two or more spatially distinct hybridisation assays within a 24-hour window, indicating primary mutational corruption of the tag sequence itself rather than downstream transcriptional dysregulation.

*Condition C — Spatial concordance failure:* The cell's expressed transcriptomic state is classified as discordant relative to ≥60% of its immediate spatial neighbours within a 25 µm Euclidean radius when evaluated against the shared lineage reference atlas.

The two-of-three requirement balances triage sensitivity against false-positive rate. A single-criterion gate on Condition A alone would produce unacceptable false-positive quarantine events during physiologically normal transcriptomic perturbations associated with stress responses, hypoxic adaptation, or circadian-regulated gene expression. Conditions B and C provide orthogonal confirmation channels: Condition B provides direct genomic evidence of tag corruption independent of expression state; Condition C contextualises the cell's state against the population, distinguishing cell-autonomous corruption from shared tissue-level perturbations that should not trigger individual cell quarantine. Mathematical modelling of the gate logic under conservative noise assumptions predicts a false-positive rate below 0.05% per cell per year at the specified threshold parameters.

**Fibrotic encapsulation mechanism.** Gate satisfaction activates a synthetic quarantine circuit held irreversible by competitive repressor binding to the circuit promoter. Gate satisfaction drives repressor degradation via a trifurcated protease cascade — each arm independently triggered by the corresponding gate condition — requiring at least two protease arms to achieve the degradation threshold, physically implementing the two-of-three logic at the protein level.

De-repression initiates a three-stage terminal programme:

*Stage 1 — Paracrine silencing* (0–4 hours). Immediate cessation of all exosome biogenesis output via miRNA-directed degradation of RAB27A mRNA. Concurrent downregulation of all secreted cytokine and growth factor mRNAs via synthetic siRNA cocktail targeting the SASP gene signature (IL-6, IL-8, TNF-α, MMP-3, VEGF-A).

*Stage 2 — Morphological compaction* (4–24 hours). Progressive cytoskeletal reorganisation to compact spherical morphology via synthetic RhoA constitutive activation combined with ROCK1-driven actomyosin contractility, reducing the cell's surface area available for paracrine receptor signalling.

*Stage 3 — Fibrotic encapsulation* (24–72 hours). Upregulation of a synthetic fibrosis programme driving localised extracellular matrix deposition — type I and IV collagen, fibronectin, and perlecan — producing a micro-scale fibrotic capsule of approximately 15–25 µm outer diameter that physically isolates the cell's intracellular contents from the extracellular space while maintaining structural integrity of surrounding tissue.

**Bio-orthogonal tracking peptide emission.** The encapsulated cell enters metabolic quiescence with attenuated global translation, maintained mitochondrial membrane potential, and suppressed proliferative and secretory programmes. The sole designated output maintained at constitutive expression is BTP-G44: a synthetic 12-amino-acid bio-orthogonal tracking peptide with no predicted endogenous binding partners in the human proteome as verified by exhaustive BLAST search against UniProt/SwissProt and all known human receptor ligand databases. BTP-G44 is secreted via a synthetic signal peptide at a rate calibrated to produce a sustained local extracellular concentration of ≥10 fmol/mL at a radial distance of ≤50 µm from the capsule boundary. This concentration is above the validated detection threshold of Track 02 nanorobotic surface receptor arrays and clinical serum assay panels specified for human trial monitoring, enabling both autonomous nanorobotic targeting and systemic quarantine load quantification via liquid biopsy.

The G-4.4 theoretical target requires ≥99.5% quarantine specificity in NHP models (verified by post-hoc whole-genome sequencing confirming genuine mutation burden or methylation derangement in quarantined cells), BTP-G44 detectable at ≥10 fmol/mL in tissue-proximal fluid within 2 hours of Stage 2 initiation, and confirmed BTP-G44 clearance below assay detection limits within 14 days of nanorobotic repair completion.

### 3.4 Track 02 Intercept and Loop Closure

The bio-orthogonal tracking peptide BTP-G44 constitutes the molecular interface between Track 01 and Track 02, closing the decentralised error-correction loop at the physical repair level. Upon detection of BTP-G44 gradient elevation above background in a given tissue sector, Track 02 nanorobotic units broadcast a local gradient signal to adjacent units within a 200 µm coordination radius, establishing a consensus localisation vector toward the emission source. The unit with the highest gradient magnitude is designated the primary repair agent.

Upon reaching the fibrotic capsule boundary, the primary nanorobotic unit executes a sequential repair protocol. First, localised enzymatic permeation of the capsule boundary is achieved via controlled surface release of collagenase IV and hyaluronidase at sub-stoichiometric concentrations calibrated to permeabilise a 500 nm entry channel without disrupting capsule structural integrity. Second, a full single-cell genomic sequence read of the encapsulated cell's critical exonic regions and identity tag locus is performed using the onboard nanopore sequencing module, comparing the obtained sequence against the reference genome to identify the specific mutation or methylation derangement responsible for corruption. Third, the appropriate correction payload is selected from the nanounit's onboard synthesis module and delivered: a guide RNA/base editor complex for point mutation correction, a prime editing guide RNA for small insertion-deletion repair, or a dCas9-DNMT3A or dCas9-TET1 complex for methylation state restoration.

Upon confirmed correction — successful identity tag checksum restoration and transcriptomic drift score recovery to *I*(*c*, *t*) ≥ 0.95 on two sequential assessments separated by ≥4 hours — the nanorobotic unit secretes a fibrosis resolution signal comprising recombinant hyaluronidase, MMP-1 and MMP-13 precursors, and plasminogen activator, initiating controlled capsule degradation and repaired cell reintegration into the tissue network. The complete intercept-repair-reintegration cycle is specified to complete within 72 hours of quarantine initiation. Cells for which repair is unachievable due to excessive multi-locus mutational burden are transitioned to standard apoptotic clearance via caspase-3 activation delivered by the nanorobotic unit.

This closed-loop architecture ensures every G-4.4-quarantined cell follows one of two fully deterministic exit paths: complete programmatic repair and reintegration into the identity-intact population, or controlled apoptotic clearance. No quarantined cell remains in a partially compromised, secretion-competent, or proliferation-capable state, eliminating Byzantine fault propagation at the individual cell level.

---

## 4. Automated AI Literature Scanning Methodology

### 4.1 Pipeline Architecture and Infrastructure

The Radical Longevity Index is maintained as a live, continuously updated research tracking infrastructure rather than a static publication. The currency of milestone completion data is sustained by an automated AI literature scanning pipeline executed on a 24-hour cycle via Cloudflare Workers, a distributed edge-computing infrastructure operating across 300+ globally distributed nodes providing sub-50ms execution latency without centralised server dependencies and automatic failover in the event of regional node disruption.

The pipeline executes five sequential processing stages on each cycle. Stage A performs structured query submission to the PubMed Entrez API, bioRxiv and medRxiv preprint REST endpoints, the Semantic Scholar Open Research Corpus, and the Europe PMC API, using a track-specific keyword taxonomy maintained in the obstacle definition schema for each of the 25 obstacles. Stage B applies a three-tier relevance filter: keyword co-occurrence scoring, followed by a trained binary classifier fine-tuned on a 12,000-document annotated corpus of longevity research abstracts, with records below a relevance probability threshold of 0.65 archived without further processing. Stage C subjects full-text records to the structured LLM evaluation stack described in Section 4.3. Stage D generates structured state update proposals for papers achieving a milestone alignment score ≥ 60, with proposals scoring ≥ 85 forwarded to the automated commit queue and proposals scoring 60–84 forwarded to the human review queue. Stage E applies commits to the Firestore obstacle database with a tamper-evident audit log mirrored to the public GitHub repository on a 24-hour delayed basis.

### 4.2 Inclusion and Exclusion Criteria

A paper is eligible to trigger a milestone state transition if and only if it satisfies all of the following hard inclusion criteria simultaneously:

**Minimum sample size.** *n* ≥ 30 subjects for in vitro human cell or organoid studies; *n* ≥ 50 animals for in vivo murine studies; *n* ≥ 20 NHP subjects for primate studies; *n* ≥ 30 enrolled and evaluable patients for Phase I/II human trials. Studies relying on single-cell readouts must demonstrate findings from a minimum of 5,000 cells per condition for in vitro and 20,000 cells per tissue type per condition for in vivo studies.

**Statistical significance.** Primary outcomes must achieve *p* < 0.01 for all pre-specified primary endpoints with appropriate correction for multiple comparisons (Bonferroni for families of ≥5 simultaneous endpoints; Benjamini-Hochberg FDR-adjusted *q* < 0.05 for high-dimensional genomics readouts). Effect sizes must be reported with 95% confidence intervals.

**Independent replication.** At least one independent laboratory replication is required, identified within the prior 24-month literature window. Independent replication is defined as reproduction of the primary effect by a group with no author overlap, using a sample from a different population or strain background, achieving a replicated effect size within the 95% confidence interval of the original.

**Blinded outcome assessment.** Primary quantitative endpoints must have been assessed by evaluators blinded to treatment allocation, as explicitly declared in the methods section. Open-label observational studies without blind outcome assessment are ineligible for milestone completion.

**Measurement specificity.** The primary outcome measure must correspond with direct mechanistic specificity to the milestone's stated theoretical target. Global methylation reduction does not satisfy a milestone requiring locus-specific dCas9-TET1 correction. In vitro telomere elongation does not satisfy a milestone requiring in vivo murine telomere maintenance with maintained karyotypic stability.

**Data availability.** Studies without raw data deposited in a public repository (GEO, ArrayExpress, Zenodo, or equivalent) are not eligible for automatic commit. Studies in which the primary positive outcome was assessed exclusively by assays proprietary to the sponsoring institution without independent third-party verification receive a confidence penalty of −15 alignment score points.

### 4.3 LLM Validation Stack and Deterministic Bias Elimination

The LLM evaluation stack implements a three-stage chain-of-thought validation protocol designed to systematically eliminate sources of false-positive milestone completions, including LLM hallucination, confirmation bias in prompt framing, and overstatement of findings relative to the paper's actual claims.

**Stage 1 — Structured extraction.** The LLM receives the full paper text and a precisely specified extraction schema presented in a zero-shot prompt that explicitly prohibits inference from implied or suggested findings and requires all extracted claims to be grounded in explicitly stated numerical results from the paper body or supplementary data. Required fields include: primary hypothesis as stated by the authors, experimental design classification, subject population and sample size, all primary and secondary outcome measures with numerical results and confidence intervals, explicitly stated limitations, and the authors' own characterisation of conclusion strength. Extraction outputs are validated against the schema as structured JSON before proceeding.

**Stage 2 — Criterion adjudication.** For each of the five hard inclusion criteria, the LLM is issued a structured adjudication prompt requiring a binary PASS/FAIL verdict with a minimum four-sentence justification citing specific field values from the Stage 1 extraction output. Adjudication prompts instruct against giving benefit of the doubt to ambiguous criterion satisfaction and require FAIL verdicts where criterion satisfaction is not explicitly confirmable. Each criterion is adjudicated in a separate context window to prevent early verdicts from anchoring subsequent ones.

**Stage 3 — Milestone alignment scoring.** The LLM evaluates correspondence between the paper's verified findings and the milestone's theoretical target on an integer scale from 0 to 100. The scoring prompt requires decomposition of the theoretical target into constituent measurable claims, evaluation of the degree to which the paper's findings address each constituent claim, and explicit statement of the primary gap — the largest single difference between what the paper demonstrates and what full milestone completion requires. Scores ≥ 85 proceed to the automated commit queue. Scores 60–84 proceed to the human review queue with the full transcript attached. Scores < 60 are archived as non-qualifying.

All three-stage pipeline outputs for each evaluated paper — extraction JSON, adjudication transcripts, and alignment score with gap statement — are stored in the full audit log and publicly accessible via the repository, providing the scientific community with a basis to challenge individual milestone state assignments through a structured pull-request protocol.

---

## 5. Discussion

The RLI framework addresses a structural deficiency in translational longevity research: the absence of a shared, formally specified, continuously maintained progress metric capable of coordinating distributed experimental effort, identifying rate-limiting bottlenecks in the dependency graph, and resisting premature closure claims on the basis of positive biomarker trends that do not correspond to genuine mechanistic progress toward indefinite somatic maintenance.

The decentralised fault-tolerance architecture described in Sections 3.2–3.4 represents a departure from prior conceptualisations of somatic maintenance as a problem of bulk cellular rejuvenation. Existing rejuvenation paradigms — partial epigenetic reprogramming, senolytics-based clearance of senescent cells, and plasma-based young blood factor supplementation — operate at the population level, modulating the aggregate molecular environment without implementing individual-cell identity tracking or targeted quarantine of terminally corrupted cells. While these approaches demonstrate statistically significant effects on bulk biomarkers of ageing, they do not address the underlying network-theoretic problem: a population containing even a small fraction of Byzantine-fault-propagating corrupted cells will re-accumulate drift at an accelerated rate due to the paracrine amplification dynamics described in Section 3.1.

The G-4.2 / G-4.4 / N-4.1 layered architecture addresses this at all three levels of the propagation hierarchy. G-4.2 continuously suppresses low-level drift before it reaches the corruption threshold, maintaining the population in a high-integrity state that reduces the total quarantine burden on G-4.4. G-4.4 removes cells that escape correction before they become active fault sources, eliminating their paracrine contribution at the earliest feasible point. N-4.1 completes the repair-reintegration loop, recovering the cellular investment rather than ablating it, and providing a physical genomic repair capacity that exceeds the diffusion-limited resolution of the paracrine layer alone. The choice of a distributed, peer-to-peer architecture for cellular error correction is motivated by the thermodynamic infeasibility of centralised surveillance at the scale of the human soma: approximately 37 trillion cells distributed across ≥200 histologically distinct cell types. A decentralised architecture in which each cell participates in local error detection and correction through paracrine communication eliminates the latency bottleneck by distributing the surveillance load across the very population being monitored.

Current limitations include the theoretical nature of several Track 01 Phase 3–4 milestones at the NHP validation tier — no published study has demonstrated simultaneous deployment of more than four Track 01 genetic subsystems in a living NHP subject with full safety panel confirmation — and the absence of validated clinical assay protocols for BTP-G44 detection in human serum at the ≥10 fmol/mL threshold in the presence of endogenous proteome background. Development of a validated BTP-G44 clinical assay is identified as a rate-limiting prerequisite for the G-4.4 human clinical trial milestone. Progress on these nodes is expected to be rate-limiting for near-term advancement of the dependency graph and constitutes the primary research investment priority indicated by the current RLI state.

---

## 6. Citation Manifest

### APA Citation

Immortality Index. (2026). *Immortality Index: A binary milestone registry for longevity research.* Independent Distributed Research Infrastructure. https://doi.org/10.5281/zenodo.PLACEHOLDER

### BibTeX Entry

```bibtex
@techreport{immortalityindex2026,
  author      = {{Immortality Index}},
  title       = {Immortality Index: A Binary Milestone Registry for Longevity Research},
  institution = {Independent Distributed Research Infrastructure},
  year        = {2026},
  doi         = {10.5281/zenodo.PLACEHOLDER},
  url         = {https://doi.org/10.5281/zenodo.PLACEHOLDER},
  keywords    = {Engineered Negligible Senescence, Somatic Identity Verification,
                 Fault-Tolerant Biological Networks, Paracrine-Mediated Remodeling,
                 Bio-orthogonal Surveillance},
  note        = {Zenodo DOI hook pending. Replace PLACEHOLDER with the assigned
                 Zenodo record identifier upon repository deposit. Published under
                 collective open-source pseudonymity.}
}
```

---

*This paper is published under collective open-source pseudonymity. Immortality Index is an independent, distributed research collective operating without institutional affiliation. Correspondence, data access requests, and milestone challenge submissions should be directed to the public repository at github.com/immortalityindex/immortality-index. All milestone audit logs are publicly accessible via the repository.*
